BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27594591)

  • 1. Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma.
    Dey M; Yu D; Kanojia D; Li G; Sukhanova M; Spencer DA; Pituch KC; Zhang L; Han Y; Ahmed AU; Aboody KS; Lesniak MS; Balyasnikova IV
    Stem Cell Reports; 2016 Sep; 7(3):471-482. PubMed ID: 27594591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
    Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
    Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
    Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
    Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
    Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
    Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.
    Zhang J; Chen H; Chen C; Liu H; He Y; Zhao J; Yang P; Mao Q; Xia H
    Cancer Lett; 2021 Jul; 509():26-38. PubMed ID: 33819529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction.
    Morshed RA; Gutova M; Juliano J; Barish ME; Hawkins-Daarud A; Oganesyan D; Vazgen K; Yang T; Annala A; Ahmed AU; Aboody KS; Swanson KR; Moats RA; Lesniak MS
    Cancer Gene Ther; 2015 Jan; 22(1):55-61. PubMed ID: 25525033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
    Kostova Y; Mantwill K; Holm PS; Anton M
    Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.
    Kim CK; Ahmed AU; Auffinger B; Ulasov IV; Tobias AL; Moon KS; Lesniak MS
    Mol Ther; 2013 Nov; 21(11):2063-73. PubMed ID: 23883863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.
    Ahmed AU; Thaci B; Alexiades NG; Han Y; Qian S; Liu F; Balyasnikova IV; Ulasov IY; Aboody KS; Lesniak MS
    Mol Ther; 2011 Sep; 19(9):1714-26. PubMed ID: 21629227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy.
    Li X; Mao Q; Wang D; Xia H
    Int J Oncol; 2012 Dec; 41(6):2159-65. PubMed ID: 23117867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.
    Okemoto K; Kasai K; Wagner B; Haseley A; Meisen H; Bolyard C; Mo X; Wehr A; Lehman A; Fernandez S; Kaur B; Chiocca EA
    Clin Cancer Res; 2013 Nov; 19(21):5952-9. PubMed ID: 24056786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells.
    Czolk R; Schwarz N; Koch H; Schötterl S; Wuttke TV; Holm PS; Huber SM; Naumann U
    Int J Mol Med; 2019 Oct; 44(4):1484-1494. PubMed ID: 31432139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
    Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
    Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enterovirus A71 Oncolysis of Malignant Gliomas.
    Zhang X; Wang H; Sun Y; Qi M; Li W; Zhang Z; Zhang XE; Cui Z
    Mol Ther; 2020 Jun; 28(6):1533-1546. PubMed ID: 32304669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of glioma in rat models by intranasal application of parvovirus h-1.
    Kiprianova I; Thomas N; Ayache A; Fischer M; Leuchs B; Klein M; Rommelaere J; Schlehofer JR
    Clin Cancer Res; 2011 Aug; 17(16):5333-42. PubMed ID: 21715567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
    Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
    Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.
    Vera B; Martínez-Vélez N; Xipell E; Acanda de la Rocha A; Patiño-García A; Saez-Castresana J; Gonzalez-Huarriz M; Cascallo M; Alemany R; Alonso MM
    PLoS One; 2016; 11(1):e0147211. PubMed ID: 26808201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
    Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
    Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.